22 |
Klinisk Biokemi i Norden · 3 2018
Referenser
1. Fagerhol M, Dale I, Andersson T. A radioimmu-
noassay for a grannulcyte protein as a marker in
studies on the turnover of such cells. Bull Eur
Physiopathol Respir 1980;16(Suppl):273-82.
2. Steinbakk M, Naess-Andressen C, Lingaas E,
Dale I, Brandzaeg P, Fagerhol MK. Antimicro-
bial actions of calcium binding leucocyte L1
protein, calprotectin. Lancet 1990;336:763-5.
3. Rheenen PF, Van de Vijver E, Fidler V. Faecal
calprotectin for screening of patients with sus-
pected inflammatory bowel disease: diagnostic
meta-analysis. BMJ 2010;341:1-11.
4. Sipponen T, Savilahti E, Kärkkäinen P, Kolho
KL, Nuutinen T, Turunen U, Färkkilä M. Fecal
calprotectin, lactoferrin, and endoscopic dis-
ease activity in monitoring anti-TNF-alpha
therapy for Crohn’s disease. Inflamm Bowel
Dis 2008;14:1392-8.
5. Kalla R, Kennedy NA, Ventham NT, Boyapati
RK, Adams AT, Nimmo ER, et al. Serum Cal-
protectin: A novel diagnostic and prognostic
marker in inflammatory bowel diseases. Am J
Gastroenterol 2016;111:1796-1805.
6. Ricanek P, Brackmann S, Perminow G, Lycka-
nder LG, Sponheim J, Holme O, et al. IBSEN
II Study Group. Evaluation of disease activity
in IBD at the time of diagnosis by the use of
clinical, biochemical, and fecal markers. Scand
J Gastroenterol 2011;46:1081-91
7. Molander P, af Björkesten CG, Mustonen H,
Haapamäki J, Vauhkonen M, Kolho KL, et
al. Fecal calprotectin concentration predicts
outcome in Inflammatory bowel disease after
Induction therapy with TNFa blocking agents.
Inflamm Bowel Dis 2012;18:2011-7.
8. Schoepfer AM, Beglinger C, Straumann A,
Safroneeva E, Romero Y, Armstrong D, et al.
Fecal calprotectin more accurately reflects
endoscopic activity of ulcerative colitis than the
Lichtiger Index, C-reactive protein, platelets,
hemoglobin, and blood leukocytes. Inflamm
Bowel Dis 2013; 19: 332–341.
9. Costa F, Mumolo MG, Ceccarelli L, Bellini
M, Romano MR, Sterpi C, et al. Calprotectin
is a stronger predictive marker of relapse in
ulcerative colitis than in Crohn’s disease. Gut
2005;54:364–8.
10. D’Haens G, Ferrante M, Vermeire S, Baert F,
NomanM, Moortgat L, et al. Fecal calprotectin
is a surrogate marker for endoscopic lesions in
inflammatory bowel disease. Inflamm Bowel
Dis 2012;18: 2218–2224.
11. af Björkesten CG, Nieminen U, Sipponen T,
Turunen U, Arkkila P, Färkkilä M. Surrogate
markers and clinical indices, alone or com-
bined, as indicators for endoscopic remission
in anti-TNF-treated luminal Crohn’s disease.
Scand J Gastroenterol. 2012;47(5):528-37.
12. Nieminen U, Jussila A, Nordling S, Mustonen
H, Färkkilä MA. Inflammation and disease
duration have a cumulative effect on the risk of
dysplasia and carcinoma in IBD: a case-control
observational study based on registry data. Int
J Cancer. 2014 Jan 1;134:189-96.
13. Vinding KK, Elsberg H, Thorkilgaard T, Belard
E, Pedersen N, Elkjaer M, et al. Fecal calpro-
tectin measured by patients at home using
smartphones—a new clinical tool in monitor-
ing patients with inflammatory bowel disease.
Inflamm Bowel Dis 2016;22:336–44.
14. Elkjaer M, Shuhaibar M, Burisch J, Bailey Y,
Scherfig H, Laugesen B, et al. E-health empow-
ers patients with ulcerative colitis: a randomised
controlled trial of the web-guided ‘Constant-
care’ approach. Gut 2010;59:1652-61.
15. Puolanne AM, Kolho KL, Alfthan H, Ristimäki
A, Mustonen H, Färkkilä M. Rapid fecal calpro-
tectin test and symptom index in monitoring
the disease activity in colonic inflammatory
bowel disease. Dig Dis Sci 2017;62:3123-30.
16. Heida A, Knol M, Kobold AM, Bootsman
J, Dijkstra G, van Rheenen PF. Agreement
between home-based measurement of stool
calprotectin and ELISA results for monitor-
ing inflammatory bowel disease activity. Clin
Gastroenterol Hepatol 2017;15:1742-9.
17. D’Angelo F, Felley C, Frossard JL. Calprotectin
in Daily Practice: Where DoWe Stand in 2017?
Digestion 2017;95:293-301.
18. Molander P, Färkkilä M, Ristimäki A, Salminen
K, Kemppainen H, Blomster T, et al. Does fecal
calprotectin predict short-term relapse after
stopping TNFα-blocking agents in inflamma-
tory bowel disease patients in deep remission?
J Crohns Colitis. 2015;9(1):33-40.
